share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4:持股變動聲明-高管 Gibson Christopher
美股SEC公告 ·  08/30 04:26
牛牛AI助理已提取核心訊息
Christopher Gibson, CEO of Recursion Pharmaceuticals, has engaged in a stock purchase transaction for the company's shares. On August 29, 2024, Gibson acquired 5,000 shares of Recursion Pharmaceuticals' Class A Common Stock at a price of $2.48 per share. This transaction is part of an exercise or conversion of a derivative security. Following this acquisition, Gibson's direct holdings in the company increased to a total of 757,656 shares. The transaction is currently in progress.
Christopher Gibson, CEO of Recursion Pharmaceuticals, has engaged in a stock purchase transaction for the company's shares. On August 29, 2024, Gibson acquired 5,000 shares of Recursion Pharmaceuticals' Class A Common Stock at a price of $2.48 per share. This transaction is part of an exercise or conversion of a derivative security. Following this acquisition, Gibson's direct holdings in the company increased to a total of 757,656 shares. The transaction is currently in progress.
Recursion Pharmaceuticals的首席執行官Christopher Gibson進行了公司股票的股票購買交易。2024年8月29日,Gibson以每股2.48美元的價格購買了Recursion Pharmaceuticals的A類普通股5,000股。該交易是對衍生證券的行權或轉換的一部分。在此次收購之後,Gibson在該公司的直接持股增加到757,656股。該交易目前正在進行中。
Recursion Pharmaceuticals的首席執行官Christopher Gibson進行了公司股票的股票購買交易。2024年8月29日,Gibson以每股2.48美元的價格購買了Recursion Pharmaceuticals的A類普通股5,000股。該交易是對衍生證券的行權或轉換的一部分。在此次收購之後,Gibson在該公司的直接持股增加到757,656股。該交易目前正在進行中。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。